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Before licensing, ipilimumab was first made available to
previously treated advanced melanoma patients through an
expanded access programme (EAP) across Europe. We
interrogated data from UK EAP patients to inform future
clinical practice. Clinicians registered in the UK EAP provided
anonymized patient data using a prespecified variable fields
datasheet. Data collected were baseline patient
characteristics, treatment delivered, toxicity, response,
progression-free survival and overall survival (OS). Data were
received for 193 previously treated metastatic melanoma
patients, whose primary sites were cutaneous (82%), uveal
(8%), mucosal (2%), acral (3%) or unknown (5%). At baseline,
88% of patients had a performance status (PS) of 0–1 and
20% had brain metastases. Of the patients, 53% received all
four planned cycles of ipilimumab; the most common reason
for stopping early was disease progression, including death
from melanoma. Toxicity was recorded for 171 patients, 30%
of whom experienced an adverse event of grade 3 or higher,
the most common being diarrhoea (13%) and fatigue (9%). At
a median follow-up of 23 months, the median progression-
free survival and OS were 2.8 and 6.1 months, respectively;
the 1-year and 2-year OS rates were 31 and 14.8%,
respectively. The 2-year OS was significantly lower for
patients with poorer PS (P<0.0001), low albumin
concentrations (P<0.0001), the presence of brain
metastases (P=0.007) and lactate dehydrogenase levels
more than two times the upper limit of normal (P<0.0001) at
baseline. These baseline characteristics are negative
predictors of benefit from ipilimumab and should be taken
into consideration before prescription. Melanoma Res
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Introduction
Melanoma is the cause for more than 12 000 patient
deaths across Europe each year (http://eco.iarc.fr/eucan
/Cancer.aspx?Cancer= 20-block-table-m). The incidence is
increasing rapidly worldwide, particularly because of
environmental and behavioural factors associated with
ultraviolet light exposure. Until recently, patients with
advanced, unresectable melanoma had a median life
expectancy of around 8 months, with limited treatment
options, which did not impact survival. Ipilimumab is a
fully human monoclonal antibody that blocks CTLA-4
from binding to its ligands, B7-1 and B7-2, on antigen-
presenting cells, potentiating a cytotoxic T-cell response.
In 2010, ipilimumab became the first systemic therapy to
show a survival benefit in previously treated advanced
melanoma patients in an international multicentre
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randomized phase III trial [1], achieving a median overall
survival (OS) benefit of 10 months, compared with
6.4 months (hazard ratio 0.68, P< 0.01) in the control
(gp100 vaccine) arm. A first-line trial [2] demonstrated
that ipilimumab combined with dacarbazine improved
the median OS to 11.2 months versus 9.1 months with
dacarbazine alone (HR 0.72, P< 0.001). The results led
to licensing of ipilimumab in both settings.
Longer follow-up of increasing numbers of advanced
melanoma patients recruited to ipilimumab trials, as well
as expanded access programmes (EAPs) worldwide, has
confirmed that, in those patients who benefit from
treatment, survival gain is sustained over several years,
with a 3-year OS rate in the order of 20% [3]. Even so,
most patients receiving ipilimumab do not benefit from
treatment, and biomarkers predictive of response remain
elusive. Ipilimumab is now routinely available in most
western countries, and the licensed indication is less
stringent than the registration clinical trial eligibility cri-
teria; hence, patient access has extended to a wider
melanoma population than that originally rigorously stud-
ied. The health economic burden of this high-cost drug,
alongside significant drug-related toxicity, which is life-
threatening in some instances [1,2], is considerable: the
sales of ipilimumab in 2013 totalled $960M.
Before licensing, international EAPs afforded doctors and
patients alike early access to and experience with ipili-
mumab. Clinicians treating patients in the EAP were
required to register and complete a training programme
set by the manufacturer to assure patient safety. The
drug was supplied free of charge. These registered
patient cohorts provide a useful window to interrogate
patient outcomes in a routine clinical setting. We
undertook a retrospective review of previously treated
advanced melanoma patients in the UK who accessed
ipilimumab in the European EAP and compared their
outcomes with relevant clinical trial and EAP patient data
reported in the literature to date.
Methods
This was an ethics committee-approved, retrospective
cohort study of UK advanced melanoma patients who
met the criteria to access ipilimumab through an EAP
provided by Bristol Myers Squibb in Europe between
2010 and 2011. Patients were required to have had pre-
viously treated, unresectable American Joint Committee
on Cancer (AJCC) stage III or IV metastatic melanoma.
Patients with brain metastases were not excluded as long
Table 1 Patient baseline characteristics
Variable n (%) (N=193)
Age (years)
n 193
Median 60
Range 25–81
Sex
Male 114 (59)
Female 79 (41)
Primary site
Cutaneous 158 (82)
Uveal 15 (8)
Acral 6 (3)
Mucosal 4 (2)
Unknown 10 (5)
ECOG PS
0 66 (35)
1 100 (53)
2 22 (12)
3 2 (1)
Unknown 3
AJCC disease stage
M1a 22 (11)
M1b 25 (13)
M1c 144 (75)
III/IV 2 (1)
Presence of brain metastases
No 140 (80)
Yes 35 (20)
Unknown 18
LDH>2×ULN
No 130 (73)
Yes 49 (27)
Unknown 14
LDH>1×ULN
No 48 (27)
Yes 131 (73)
Unknown 14
Albumin≥35
No 35 (27)
Yes 97 (73)
Unknown 64
BRAF status
Mutant 20 (28)
Wild type 51 (72)
Unknown 122
Prior lines of treatment
0 2 (1)
1 123 (77)
2 25 (16)
3 9 (6)
4 1 (1)
Unknown 33
Prescribed steroids
No 108 (83)
Yes 22 (17)
Unknown 63
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative
Oncology Group; LDH, lactate dehydrogenase; PS, performance status; ULN,
upper limit of normal.
Table 2 Frequency of CTCAE grade≥3 adverse events reported
AEs n (%) (N=171)
Diarrhoea 22 (13)
Fatigue 15 (9)
Pain 5 (3)
Rash 5 (3)
Deranged AST/ALT 4 (2)
Nausea 3 (2)
Hypophysitis 3 (2)
Anaemia 2 (1)
Pruritus 2 (1)
SIADH 2 (1)
Cough 1 (1)
Thrombocytopenia 1 (1)
Uveitis 1 (1)
Thyroiditis 1 (1)
Other 3 (2)
AE, adverse event; ALT, alanine transaminase; AST, aspartate aminotransferase;
CTCAE, common terminology criteria for adverse events; SIADH, syndrome of
inappropriate antidiuretic hormone secretion.
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as they were asymptomatic, stable and used systemic
steroids at the lowest clinically effective dose.
All patients were to be administered 3 mg/kg ipili-
mumab, three times a week, intravenously, for up to four
cycles.
Design of study and data collection
Information was retrospectively collated by reviewing
case notes of patients registered in the EAP. A standard
anonymous data collection form was designed to collect
data on patient characteristics before treatment: age, sex,
Fig. 1 (Continued)
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primary site of melanoma, disease stage, presence or
absence of brain metastases, Eastern Cooperative
Oncology Group (ECOG) performance status (PS),
serum lactate dehydrogenase (LDH) level and albumin
level. Data on the treatment delivered, including start
date, dates of each cycle delivered, total number of
cycles, drug doses, treatment modifications and reasons
for modification, were recorded. Toxicity was assessed on
the basis of internationally defined criteria (NCI CTCAE
4.03). Response was assessed by the investigators, with
categories assigned retrospectively according to RECIST
1.1, clinical, or other. Progression-free survival (PFS) and
OS were measured from the date of starting treatment.
Statistical analysis
PFS was defined from the date of starting ipilimumab
treatment until the date of progression or the date of
death from all causes, whichever occurred first; patients
with unknown progression status at the time of data
collection were censored at the date they were last
known not to have progressed. OS was defined from the
date of starting ipilimumab until the date of death from
all causes; surviving patients at the time of data collection
were censored at the date they were last known to be
alive. PFS and OS were estimated using Kaplan–Meier
analysis. Initially the subgroup analyses were to be car-
ried out using the log-rank test on OS by age (≤ 60 vs.
> 60 years), sex, ECOG PS (0 vs. 1 vs. 2/3) and ECOG PS
(0/1 vs. 2/3), disease stage (cutaneous vs. uveal vs. acral
vs. mucosal vs. unknown) and disease stage (uveal vs.
other), brain involvement (yes vs. no), albumin level
(≤ 35 vs. > 35 g/l) and LDH level greater than one time
and two times the upper limit of normal (ULN; yes vs.
no). Multivariate analyses were carried out after the initial
analyses. Univariate and multivariate analyses using Cox
regression models were reported. In addition, the correl-
ation between the number of cycles and the ECOG PS
was estimated after the initial analysis.
The OS of the UK EAP cohorts were compared with the
results of the published cohorts, with their data read from
the OS curves. A review of the literature and a literature
search were performed as described by Chasset et al. [4].
Briefly, we searched EMBASE (1974–January 2014),
MEDLINE (1966–February 2015) and the Cochrane
Database of Systematic Reviews (The Cochrane Library,
2015, issue 1) for original articles without language
restrictions. The search strategy combined free text
search, exploded MESH/EMTREE terms and all syno-
nyms of the following Medical Subject Headings terms:
ipilimumab, immunotherapy, compassionate use,
expanded access programme, melanoma. We also search-
ed for additional articles from the reference lists of rele-
vant papers obtained within the electronic search. The
grey literature was also explored through a manual search
of conference abstracts from the European Cancer
Congress and the American Society of Clinical Oncology.
Results
Data collection forms were sent to 30 UK sites registered
in the EAP and were returned from 17 of those sites.
Data were collected on 195 patients, representing 70% of
all UK patients registered in the ipilimumab EAP. Two
patients did not go on to receive treatment because of
deterioration in health. Therefore, data on 193 patients
treated between 29 June 2010 and 20 September 2011
were included in the analyses. The dataset was locked for
final analysis on 10 July 2014.
Key patient characteristics are summarized in Table 1.
The median age of the patients treated was 60 years
(range 25–81 years). Of the patients, 166 had PS 0 or 1 at
the time of starting ipilimumab, 22 patients had PS 2 and
Table 3 Overall survival rates for all patients and subgroups defined by ECOG PS, serum albumin level, LDH level and the presence or
absence of brain metastases
1-year OS rate (%) 2-year OS rate (%) Median OS (months) P-value
Subgroup Rate 95% CI Rate 95% CI Median 95% CI Univariate Multivariate
ECOG 0 56 44–68 31 18–44 13.2 10.1–19.4 <0.0001 0.0002
ECOG 1 19 11–27 5.6 0–11 4.6 3.7–5.6 0.23 0.83
ECOG 2/3 13 0–26 13 0–26 3.3 1.4–4.2
Albumin≤35 6.5 0–15 7 0–15 2.9 2.0–3.3 <0.0001 0.001
Albumin>35 46 35–56 21 11–31 10.1 6.8–13.0
LDH≤2×ULN 42 34–51 20 12–29 9.6 6.7–12.1 <0.0001 0.14
LDH>2×ULN 7 0–14 0 3.2 2.0–4.3
LDH≤1×ULN 48 34–63 19 6–32 11.6 5.7–17.0 0.048
LDH>1×ULN 27 19–35 15 7–22 5.4 4.1–6.9
Brain metastases absent 34 26–42 15 7.8–21 7.2 5.2–9.1 0.0069 0.073
Brain metastases present 17 3.4–31 13 0.27–25 3.5 2.5–4.9
Uveal= no 30 23–37 15 8.7–21 6.2 4.6–7.4 0.76 0.50
Uveal= yes 39 13–64 23 0.79–46 3.8 0.95–13.6
LDH≤1.5× ULNa 45 35–55 20 11–30 10.1 6.7–13.2 0.0003 0.53
LDH>1.5× ULNa 18 9.0–26 9.5 1.5–17 4.3 3.2–6.1
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; OS, overall survival; PS, performance status; ULN, upper limit of
normal.
aPost-hoc analysis.
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two patients had PS 3. The majority of patients had
received one prior therapy; 35 patients had received two
or more lines of prior therapy. Although the vast majority
of patients had confirmed metastatic cutaneous melan-
oma, 15 patients had uveal primary sites and four had
mucosal primary sites. Of the patients, 144 were disease
stage IV M1c patients, and 35 patients had confirmed
brain metastases. Twenty-two patients were receiving
steroids at the time of starting ipilimumab, among whom
10 were known to have brain metastases. At the time of
the EAP, BRAF mutation testing was not routinely
available in the UK. Of the tumours tested, 51 were wild
type and 20 had a BRAF V600 mutation.
Treatment and toxicity
All treated patients received ipilimumab at the approved
dose of 3 mg/kg. Of the patients, 103 (53%) received the
planned four cycles of ipilimumab. Poorer PS patients
were less likely to receive the full planned treatments:
the median number of cycles delivered to patients with
PS 0–1 versus PS 2–3 was four versus two (correlation
coefficient=− 0.39, P< 0.0001). Among those patients
who failed to complete four cycles (n= 90), the main
reason for discontinuation was disease progression or
death from melanoma for 67 (74%) patients.
Toxicity data were available for 171 patients. Of the
patients, 70% were reported to have had at least one
significant toxicity, defined as any grade 3 or greater
adverse event, or any grade 1 or 2 adverse event deemed
clinically significant by the treating clinician. Fifty-two
(30%) of the 171 patients experienced CTC adverse
events of grade 3 or higher (Table 2). The most common
adverse event of grade 3 or higher was diarrhoea in 22
(13%) patients and fatigue in 15 (9%) patients. Significant
immune-related adverse events (irAEs) were reported in
69 (40%) patients and 31 (19%) patients suffered irAEs of
grade 3 or higher. Nine (10%) patients discontinued
treatment because of unacceptable toxicity: five diar-
rhoea, one fatigue, one thrombocytopenia, one aseptic
meningitis, one cardiac failure.
Three patient deaths were reported to be drug-related.
Two patients developed severe diarrhoea after a second
cycle of ipilimumab, and despite hospitalization and
high-dose steroids, they died because of bowel perfora-
tion. A third patient with a history of previous heart valve
surgery died suddenly of heart failure after her third
ipilimumab treatment. As the death occurred 2 days after
drug administration, the possibility of a drug effect could
not be excluded. No post mortem was conducted.
Table 4 Patient characteristics of those patients surviving for more
than 24 months after starting ipilimumab
Variables (n) n (%) (N=14)
Age (years)
n 14
Median 56
Range 25–70
Sex
Male 5 (36)
Female 9 (64)
Primary site
Cutaneous 13 (93)
Uveal 1 (7)
ECOG PS
0 10 (71)
1 3 (21)
2 1 (7)
AJCC disease stage
M1a 4 (29)
M1b 2 (14)
M1c 7 (50)
III/IV 1 (7)
Presence of brain metastases
No 11 (92)
Yes 1 (8)
Unknown 2
LDH>1×ULN
No 5 (38)
Yes 8 (62)
Unknown 1
Albumin≥35
No 1 (11)
Yes 8 (89)
Unknown 5
BRAF status
Mutant 3 (50)
Wild type 3 (50)
Unknown 8
Response by RECIST criteria 1.1
Progressive disease 1 (7)
Stable disease 5 (36)
Partial response 7 (50)
Complete response 1 (7)
Further lines of treatment after ipilimumab
Yes 3 (30)
No 7 (70)
Unknown 4
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; OS,
overall survival; PS, performance status; ULN, upper limit of normal.
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Outcomes
Response assessment was conducted for 188 patients:
127 (67%) using RECIST 1.1 criteria, a further 52 (28%)
by clinical assessment and nine (5%) by whole body
computed tomography-PET or MRI brain imaging not
reported according to RECIST. Among the 127 patients
with RECIST response measurements available, one
complete response (CR) and 23 partial responses (PR)
were documented, giving a 19% overall objective
response rate. All 52 patients with response assessed
clinically were reported as having progressive disease
except three patients (one PR, two stable disease). The
treatment responses recorded in nine patients who
underwent imaging but for whom RECIST measure-
ments were not submitted were as follows: one CR, one
PR, one stable disease, one mixed response, and five
progressive disease. Therefore, the overall response rate
for 188 evaluable patients was 14%.
At a median follow-up of 23 months, 42 patients were
alive, of whom 18 were alive without evidence of disease
progression. The median PFS was 2.8 months (95%
confidence interval= 2.6–2.9 months) and PFS at 1 and
2 years were 13 and 9%, respectively (Fig. 1a). The
median OS was 6.1 months (95% confidence
interval= 4.6–7.3 months) and OS at 1 and 2 years were
31 and 15%, respectively (Fig. 1b).
The 1-year and 2-year OS rates and the median OS of
patient subgroups of clinical interest are summarized in
Table 3. Patient characteristics most likely to predict
worse OS on univariate analyses were ECOG PS greater
than 0 (P< 0.0001), low serum albumin level
(P< 0.0001), serum LDH level greater than two times
the ULN (P< 0.0001) and the presence of brain metas-
tases (P= 0.0069). On multivariate analysis, statistical
significance (at P= 0.05) was reached for ECOG PS
greater than 0 and low serum albumin level, with a
nonsignificant trend for the presence versus the absence
of brain metastases (P= 0.073). The 2-year OS was 31%
for ECOG PS 0 patients, but only 7% for patients with an
ECOG PS of 1 or higher. Normal versus low serum
albumin levels were associated with a 2-year OS of 21
versus 7%. Although the median survival of patients with
brain metastases was short (3.5 months), some patients
were long-term survivors: 1-year OS was 17% compared
with 34% for those without brain involvement, whereas at
2 years, the OS rates were similar at 13 versus 15%. The
primary site of melanoma did not appear to influence OS.
The review of the 14 patients who lived for more than
2 years (Table 4) for markers of good outcome is limited
by the small cohort size. However, univariate analysis
identified baseline PS and objective response to treat-
ment as the most important factors (P= 0.01 and
< 0.0001, respectively). Three of the long-term survivors
received subsequent lines of treatment after ipilimumab:
one underwent surgical resection of peritoneal disease,Ta
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another received selective internal radiation spheres for
liver metastases and the third patient underwent metas-
tasectomy, followed by targeted therapy with a combin-
ation of dabrafenib and trametinib within a clinical trial.
In the UK cohort, 111 patients matched the eligibility
criteria of the original ipilimumab registration trial – that
is ECOG PS 0–1, nonocular primary site and no active
brain metastases. On plotting their OS against that of
patients in the registration trial, as well as other published
large nontrial datasets, the outcomes were similar (Fig. 2).
Discussion
We have reported outcomes of 193 previously treated
advanced melanoma patients who accessed ipilimumab
through the European EAP. There are clearly limitations
to this retrospective cohort study, including the potential
for patient selection bias, the wide range of patient
populations and the lack of systematic methods as well as
timing of assessments. However, this UK cohort repre-
sents the European EAP cohort with the longest follow-
up to date and provides valuable outcome data for
patients treated outside of a clinical trial. OS is an
unbiased outcome measure. These survival outcomes –
that is, a median OS of 6.1 months and a 1-year and
2-year OS of 31 and 15% – are inferior to those of the
ipilimumab registration trial [1] – that is, a median OS of
10.1 months and a 1-year and 2-year OS of 46 and 24%,
respectively – most probably reflecting wider eligibility
criteria in the EAP compared with the randomized con-
trolled trial. Outcomes of those EAP patients who met
the more restrictive trial entry criteria were more com-
parable to those of the registration trial patients (Fig. 2).
We also compared the UK EAP outcomes with outcomes
from the three largest published EAP datasets from other
European countries: Italy [5], the Netherlands [6] and
Spain [7] (Table 5, Fig. 2). The lowest median and 1-year
and 2-year OS rates were seen within the UK EAP. Of
note, the UK cohort had the highest proportion of
patients with ECOG PS greater than 0 and the highest
percentage of patients with brain metastases. These
findings argue for careful patient selection when con-
sidering this therapeutic intervention.
Most melanomas arise from the skin, but rarer sites of
origin include the uveal tract and mucosal membranes.
Uveal melanoma patients are frequently excluded from
melanoma trials because of different biology and behav-
iour compared with melanomas of cutaneous and mucosal
origin. Both UK and Italian European EAP cohorts pro-
vide useful insights into the role of ipilimumab in the
treatment of advanced uveal melanoma patients, who
were excluded from the registration trial. Both European
EAP series suggest that outcomes of these patients did
not differ greatly from those of other melanoma patients:
the Italian group reported a 1-year OS of 31% for 82
advanced uveal melanoma patients compared with 35%
for all 855 EAP patients [5,8]. In the UK cohort, 1-year
and 2-year OS were 39 and 23%, respectively, for 15
advanced uveal melanoma patients, compared with 30
and 15% for 178 patients with nonuveal melanoma.
Accepting the retrospective nature of these findings, the
data suggest that a uveal site of origin should not exclude
access to ipilimumab.
The UK EAP cohort provides important insight into
treating melanoma patients with brain metastases. The
registration ipilimumab trial excluded patients with
active, untreated brain metastases. In clinical practice at
the time, most brain metastases were diagnosed in
patients presenting with neurological symptoms, and
20% of patients in the UK EAP had confirmed brain
metastases. Specific information on their symptomatol-
ogy and use of other treatments, including neurosurgery
or radiotherapy, was not collected, but the main reason
cited for 11% of patients being on steroids at the start of
ipilimumab treatment was the presence of brain metas-
tases. Only 29% (10 out of 35) of patients with brain
metastases in the UK EAP were taking steroids before
commencing ipilimumab, which might indicate a more
favourable prognosis. Despite this, the OS of patients
with and those without brain metastases was significantly
different at 1 year (34 vs. 17%), but it was almost identical
at 2 years (15 vs. 13%; Table 3, Fig. 1), suggesting that
long-term outcome of patients with brain involvement is
not uniform. One potential explanation for these results
might be BRAF inhibitors, as a new treatment option for
controlling BRAF mutant melanoma metastasizing to the
brain [9], becoming widely available for use outside of
trials [10]. However, data on subsequent treatments
received after ipilimumab, which were available for 27
out of 35 patients with brain metastases, confirmed that
none of them received a BRAF inhibitor. Alternatively,
survival 1 year from ipilimumab treatment may be indi-
cative of long-term disease control among those patients
with brain involvement.
The median OS of patients with brain metastases in our
cohort was 3.5 months, and this is consistent with the
only published prospective, single-arm study of ipilimu-
mab in patients with brain metastases, which reported a
variable median OS depending on the presence
(3.7 months) or absence (7 months) of symptoms [11].
Further retrospective series from Italy and France report
median OS of 4.5 and 3.3 months, respectively, in
patients with brain metastases [12]. Combining systemic
therapies for melanoma with conventional treatments for
brain metastases, including whole-brain radiotherapy,
radiosurgery or indeed surgery, is an evidence-poor
region, and formal studies are needed to guide future
clinical management of this poor prognostic group.
As demonstrated by the pooled analysis of 1861 patients
recruited to phase II and III ipilimumab trials, as well as
US EAPs, long-term survival from ipilimumab is gained
by around one in five treated patients, with a 22% 3-year
440 Melanoma Research 2015, Vol 25 No 5
survival now demonstrated [3]. The challenge remains to
identify predictive markers of response, given that the
majority of treated patients will not benefit. Table 6
summarizes published experience with ipilimumab in
EAPs, highlighting factors reported to be predictive of
treatment outcome. The heterogeneity of factors illus-
trate well the absence of and need for a reliable pre-
dictive biomarker. Moreover, the majority of factors
reported significance on univariate analysis. Our UK
experience identified ECOG PS and serum albumin to
be the strongest predictors of survival in a multivariate
analysis. LDH level was reported to be the strongest
predictor of poor outcome in 166 previously treated
melanoma patients receiving ipilimumab in the EAP
conducted in the Netherlands [6]. Retrospective multi-
variate analysis of the Netherlands cohort and an inde-
pendent cohort of 64 UK patients (some of whom
received ipilimumab in the EAP and are therefore
represented in the current review) identified that long-
term survival benefit was unlikely for patients with a
baseline serum LDH level greater than two times the
ULN. In the UK patient cohort, an elevated LDH level
and the presence of brain metastases were strong pre-
dictors of poor outcome in a univariate analysis.
Consistent with the Dutch findings, an LDH level
greater than two times the ULN was a stronger predictor
than an LDH level greater than one time the ULN.
However, in our multivariate analysis, in which a total of
109 patients (82 OS events) had complete data for all
factors included, both an LDH level greater than two
times the ULN and brain metastases were of borderline
significance. We also carried out a post-hoc analysis based
on the results from the Spanish EAP, which identified
baseline lymphocyte counts over 1000/ml and an LDH
level greater than 1.5 times the ULN as factors predictive
of survival, on univariate analysis alone [7]. In the UK
cohort, an LDH level greater than 1.5 times the ULN
was statistically significant on univariate analysis; how-
ever, on multivariate analysis this was no longer the case.
These inconsistencies may reflect differences between
the national patient cohorts. For example, the UK vali-
dation cohort used by the Dutch group was confined only
to cutaneous melanoma, and 95% of its patients had PS
0–1. Alternatively, they may be illustrative of the weak-
ness of post-hoc analyses and may signify the need to
evaluate putative biomarkers in prospective studies.
Even so, there is a set of biochemical and clinical para-
meters – serum LDH and albumin levels, PS and brain
metastases – that are established poor prognostic indica-
tors in advanced melanoma, and until there is better
evidence, they should be taken into account when
selecting patients for ipilimumab treatment.
In terms of safety, a consistent theme with ipilimumab
across multiple clinical trials is risk for irAEs, and, rarely,
death due to colitis. The registration trial reported that
around 45% of patients experienced a grade 3 or 4 event,
of which 17–24% were considered to be drug-related. In
addition, 10–15% of patients were reported to experience
grade 3 or 4 immune-related toxicities, and there were
five (1%) patient deaths due to colitis or bowel perfora-
tion [1]. Routine clinical practice is often associated with
less close patient monitoring and hence with the risk of
higher rates of drug-induced deaths. In the UK, EAP,
reassuringly, 30% grade 3 or 4 toxicities were reported, of
which two-thirds were considered to be immune-related.
Treatment-related deaths resembled those reported in
the registration trial in both frequency and cause: two of
the three deaths were associated with colitis and bowel
perforation despite active intervention; the risk of death
from ipilimumab was 1.6% in the UK EAP versus 2.1% in
the registration trial.
In summary, the 193 UK melanoma patients reviewed in
this study, who were treated with ipilimumab in the
European EAP, represented a population with char-
acteristics considerably wider than those of the popula-
tion in the controlled registration trial. A consequence of
widening access to poorer prognostic group patients was
overall poorer survival outcomes, although the outcomes
of those patients matching the entry criteria of the
registration trial were similar. Our data suggest that
careful patient selection is important. In particular, ipili-
mumab should probably be avoided in patients with poor
PS and with other evidence of high tumour burden,
including low serum albumin and high LDH levels.
However, interrogation of the data suggests a similar
safety profile compared with controlled trials, whereas
our findings lend weight to the use of ipilimumab in
advanced uveal melanoma patients and selected patients
with brain metastases.
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